Allogene Therapeutics (ALLO) Competitors $2.27 -0.19 (-7.72%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ALLO vs. RLAY, FATE, BLUE, SWTX, SRRK, BEAM, NMRA, RXRX, TARS, and IMCRShould you be buying Allogene Therapeutics stock or one of its competitors? The main competitors of Allogene Therapeutics include Relay Therapeutics (RLAY), Fate Therapeutics (FATE), bluebird bio (BLUE), SpringWorks Therapeutics (SWTX), Scholar Rock (SRRK), Beam Therapeutics (BEAM), Neumora Therapeutics (NMRA), Recursion Pharmaceuticals (RXRX), Tarsus Pharmaceuticals (TARS), and Immunocore (IMCR). These companies are all part of the "biological products, except diagnostic" industry. Allogene Therapeutics vs. Relay Therapeutics Fate Therapeutics bluebird bio SpringWorks Therapeutics Scholar Rock Beam Therapeutics Neumora Therapeutics Recursion Pharmaceuticals Tarsus Pharmaceuticals Immunocore Allogene Therapeutics (NASDAQ:ALLO) and Relay Therapeutics (NASDAQ:RLAY) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, media sentiment, profitability, risk, earnings and community ranking. Which has more risk & volatility, ALLO or RLAY? Allogene Therapeutics has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500. Comparatively, Relay Therapeutics has a beta of 1.67, indicating that its share price is 67% more volatile than the S&P 500. Do insiders and institutionals hold more shares of ALLO or RLAY? 83.6% of Allogene Therapeutics shares are owned by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are owned by institutional investors. 24.3% of Allogene Therapeutics shares are owned by insiders. Comparatively, 4.3% of Relay Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media refer more to ALLO or RLAY? In the previous week, Allogene Therapeutics had 6 more articles in the media than Relay Therapeutics. MarketBeat recorded 13 mentions for Allogene Therapeutics and 7 mentions for Relay Therapeutics. Relay Therapeutics' average media sentiment score of 0.92 beat Allogene Therapeutics' score of 0.17 indicating that Relay Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allogene Therapeutics 0 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Relay Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend ALLO or RLAY? Allogene Therapeutics currently has a consensus price target of $9.73, indicating a potential upside of 328.78%. Relay Therapeutics has a consensus price target of $21.22, indicating a potential upside of 315.71%. Given Allogene Therapeutics' higher probable upside, equities analysts clearly believe Allogene Therapeutics is more favorable than Relay Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Allogene Therapeutics 0 Sell rating(s) 3 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.75Relay Therapeutics 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90 Is ALLO or RLAY more profitable? Relay Therapeutics has a net margin of 0.00% compared to Allogene Therapeutics' net margin of -223,139.98%. Relay Therapeutics' return on equity of -45.75% beat Allogene Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Allogene Therapeutics-223,139.98% -52.13% -41.29% Relay Therapeutics N/A -45.75%-40.75% Which has preferable valuation and earnings, ALLO or RLAY? Allogene Therapeutics has higher earnings, but lower revenue than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAllogene Therapeutics$90K5,288.34-$327.27M-$1.56-1.46Relay Therapeutics$25.55M33.44-$341.97M-$2.61-1.96 Does the MarketBeat Community prefer ALLO or RLAY? Allogene Therapeutics received 225 more outperform votes than Relay Therapeutics when rated by MarketBeat users. However, 67.90% of users gave Relay Therapeutics an outperform vote while only 65.57% of users gave Allogene Therapeutics an outperform vote. CompanyUnderperformOutperformAllogene TherapeuticsOutperform Votes28065.57% Underperform Votes14734.43% Relay TherapeuticsOutperform Votes5567.90% Underperform Votes2632.10% SummaryRelay Therapeutics beats Allogene Therapeutics on 9 of the 17 factors compared between the two stocks. Ad ReticulateThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There is a little known company that is changing warfare. With the backing of U.S. government contracts, this startup is reshaping the future of the U.S. military.Click here to gain instant access to one of the most exclusive pre-ipo opportunities in the market t Get Allogene Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALLO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALLO vs. The Competition Export to ExcelMetricAllogene TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$475.95M$2.94B$5.13B$8.74BDividend YieldN/A1.84%5.18%4.07%P/E Ratio-1.4617.4866.7313.27Price / Sales5,288.34226.261,265.2981.14Price / CashN/A176.5940.2135.77Price / Book1.034.056.455.92Net Income-$327.27M-$42.42M$119.73M$225.73M7 Day Performance-26.30%-10.63%-5.13%-1.34%1 Month Performance-15.61%-5.81%-2.71%1.15%1 Year Performance-23.05%24.19%31.08%24.02% Allogene Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALLOAllogene Therapeutics2.6489 of 5 stars$2.27-7.7%$9.73+328.8%-19.2%$475.95M$90,000.00-1.46232Analyst ForecastShort Interest ↓News CoverageRLAYRelay Therapeutics3.1665 of 5 stars$6.20+1.0%N/A-36.7%$830.12M$10.01M-2.38304FATEFate Therapeutics4.1486 of 5 stars$2.42-5.1%N/A-15.1%$275.59M$12.32M-1.42550Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageBLUEbluebird bio2.8835 of 5 stars$0.41+6.2%N/A-89.4%$78.67M$54.90M-0.18323Upcoming EarningsAnalyst DowngradeNews CoverageSWTXSpringWorks Therapeutics2.1308 of 5 stars$33.99+2.7%N/A+78.2%$2.52B$86.19M-7.67305Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageSRRKScholar Rock4.6067 of 5 stars$29.08+0.4%N/A+125.3%$2.33B$33.19M-13.10140Analyst ForecastAnalyst RevisionNews CoverageBEAMBeam Therapeutics3.0293 of 5 stars$27.06+3.7%N/A-3.0%$2.24B$349.64M-15.38461Short Interest ↑NMRANeumora Therapeutics1.6299 of 5 stars$13.54+4.0%N/A-9.7%$2.17BN/A-5.29108Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageRXRXRecursion Pharmaceuticals2.1209 of 5 stars$7.10+2.5%N/A-7.4%$2.00B$44.58M-4.64400Insider SellingTARSTarsus Pharmaceuticals1.7501 of 5 stars$49.42+5.6%N/A+152.8%$1.88B$17.45M-11.0350Analyst ForecastAnalyst RevisionNews CoverageIMCRImmunocore2.9264 of 5 stars$34.69+1.1%N/A-32.6%$1.74B$249.43M-36.52497 Related Companies and Tools Related Companies RLAY Competitors FATE Competitors BLUE Competitors SWTX Competitors SRRK Competitors BEAM Competitors NMRA Competitors RXRX Competitors TARS Competitors IMCR Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ALLO) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allogene Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allogene Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
